O	0	6	Breast
O	7	13	cancer
O	14	23	incidence
O	24	26	in
O	27	30	the
O	31	41	randomized
O	42	47	PEARL
O	48	53	trial
O	54	56	of
B-intervention	57	69	lasofoxifene
O	70	72	in
B-eligibility	73	87	postmenopausal
I-eligibility	88	100	osteoporotic
I-eligibility	101	106	women
O	106	107	.

O	108	117	Currently
O	118	127	available
O	128	137	selective
O	138	146	estrogen
O	147	155	receptor
O	156	166	modulators
O	167	173	reduce
O	174	177	the
O	178	182	risk
O	183	185	of
O	186	192	breast
O	193	199	cancer
O	199	200	,
O	201	204	but
O	205	209	they
O	210	213	are
O	214	217	not
O	218	224	widely
O	225	229	used
O	229	230	.

O	231	233	In
O	234	237	the
O	238	252	Postmenopausal
O	253	263	Evaluation
O	264	267	and
O	268	272	Risk
O	272	273	-
O	273	282	Reduction
O	283	287	with
O	288	300	Lasofoxifene
O	301	302	(
O	302	307	PEARL
O	307	308	)
O	309	314	trial
O	314	315	,
O	316	328	lasofoxifene
O	329	332	was
O	333	338	shown
O	339	341	to
O	342	348	reduce
O	349	352	the
O	353	357	risk
O	358	360	of
O	361	369	estrogen
O	370	378	receptor
O	378	379	-
O	379	387	positive
O	388	389	(
O	389	391	ER
O	391	392	+
O	392	393	)
O	394	400	breast
O	401	407	cancer
O	407	408	,
O	409	421	nonvertebral
O	422	425	and
O	426	435	vertebral
O	436	445	fractures
O	445	446	,
O	447	455	coronary
O	456	462	artery
O	463	470	disease
O	470	471	,
O	472	475	and
O	476	482	stroke
O	482	483	,
O	484	487	but
O	488	491	the
O	492	499	effects
O	500	502	on
O	503	508	total
O	509	515	breast
O	516	522	cancer
O	523	524	(
O	524	532	invasive
O	533	536	and
O	537	543	ductal
O	544	553	carcinoma
O	554	556	in
O	557	561	situ
O	561	562	,
O	563	565	ER
O	565	566	+
O	567	570	and
O	571	579	estrogen
O	580	588	receptor
O	588	589	-
O	589	597	negative
O	598	599	[
O	599	601	ER
O	601	602	-
O	602	603	]
O	603	604	)
O	605	608	and
O	609	611	ER
O	611	612	+
O	613	621	invasive
O	622	628	breast
O	629	635	cancer
O	636	639	are
O	640	647	unknown
O	647	648	.

O	649	663	Postmenopausal
O	664	669	women
O	670	671	(
O	671	672	n
O	673	674	=
B-total-participants	675	679	8556
O	679	680	)
O	681	685	aged
B-age	686	688	59
I-age	688	689	-
I-age	689	691	80
I-age	692	697	years
B-eligibility	698	702	with
I-eligibility	703	706	low
I-eligibility	707	711	bone
I-eligibility	712	719	density
I-eligibility	720	723	and
I-eligibility	724	730	normal
I-eligibility	731	741	mammograms
O	742	746	were
O	747	755	randomly
O	756	764	assigned
O	765	767	to
O	768	771	two
O	772	777	doses
O	778	780	of
O	781	793	lasofoxifene
O	794	795	(
O	795	796	0
O	796	797	.
O	797	799	25
O	800	803	and
O	804	805	0
O	805	806	.
O	806	807	5
O	808	810	mg
O	810	811	)
O	812	814	or
B-control	815	822	placebo
O	822	823	.

O	824	827	The
O	828	835	primary
O	836	845	endpoints
O	846	848	of
O	849	852	the
O	853	858	PEARL
O	859	864	trial
O	865	869	were
B-outcome-Measure	870	879	incidence
I-outcome-Measure	880	882	of
I-outcome-Measure	883	885	ER
I-outcome-Measure	885	886	+
I-outcome-Measure	887	893	breast
I-outcome-Measure	894	900	cancer
I-outcome-Measure	901	904	and
I-outcome-Measure	905	917	nonvertebral
I-outcome-Measure	918	927	fractures
O	928	930	at
O	931	932	5
O	933	938	years
O	938	939	.

O	940	941	A
O	942	948	nested
O	949	953	case
O	953	954	-
O	954	961	control
O	962	967	study
O	968	970	of
O	971	973	49
O	974	982	incident
O	983	989	breast
O	990	996	cancer
O	997	1001	case
O	1002	1010	patients
O	1011	1014	and
O	1015	1018	156
O	1019	1029	unaffected
O	1030	1037	control
O	1038	1046	subjects
O	1047	1051	from
O	1052	1055	the
O	1056	1061	PEARL
O	1062	1067	trial
O	1068	1071	was
O	1072	1081	performed
O	1082	1084	to
O	1085	1093	evaluate
O	1094	1103	treatment
O	1104	1111	effects
O	1112	1114	on
O	1115	1119	risk
O	1120	1122	of
O	1123	1128	total
O	1129	1132	and
O	1133	1135	ER
O	1135	1136	+
O	1137	1145	invasive
O	1146	1152	breast
O	1153	1159	cancer
O	1160	1162	by
O	1163	1171	baseline
O	1172	1177	serum
O	1178	1187	estradiol
O	1188	1191	and
O	1192	1195	sex
O	1196	1203	hormone
O	1203	1204	-
O	1204	1211	binding
O	1212	1220	globulin
O	1221	1227	levels
O	1228	1233	using
O	1234	1242	logistic
O	1243	1253	regression
O	1254	1260	models
O	1260	1261	.

O	1262	1265	Cox
O	1266	1278	proportional
O	1279	1286	hazards
O	1287	1293	models
O	1294	1298	were
O	1299	1303	used
O	1304	1306	to
O	1307	1315	evaluate
O	1316	1320	risk
O	1321	1323	of
O	1324	1329	total
O	1330	1336	breast
O	1337	1343	cancer
O	1344	1347	and
O	1348	1350	ER
O	1350	1351	+
O	1352	1360	invasive
O	1361	1367	breast
O	1368	1374	cancer
O	1375	1380	using
O	1381	1390	intention
O	1390	1391	-
O	1391	1393	to
O	1393	1394	-
O	1394	1399	treat
O	1400	1408	analysis
O	1408	1409	.

O	1410	1413	All
O	1414	1425	statistical
O	1426	1431	tests
O	1432	1436	were
O	1437	1440	two
O	1440	1441	-
O	1441	1446	sided
O	1446	1447	.

B-outcome	1448	1454	Breast
I-outcome	1455	1461	cancer
O	1462	1465	was
O	1466	1475	confirmed
O	1476	1478	in
O	1479	1481	49
O	1482	1487	women
O	1487	1488	.

O	1489	1497	Compared
O	1498	1502	with
O	1503	1510	placebo
O	1510	1511	,
O	1512	1513	0
O	1513	1514	.
O	1514	1515	5
O	1516	1518	mg
O	1519	1521	of
O	1522	1534	lasofoxifene
O	1535	1548	statistically
O	1549	1562	significantly
O	1563	1570	reduced
O	1571	1574	the
B-outcome	1575	1579	risk
I-outcome	1580	1582	of
I-outcome	1583	1588	total
I-outcome	1589	1595	breast
I-outcome	1596	1602	cancer
O	1603	1605	by
B-iv-bin-percent	1606	1608	79
I-iv-bin-percent	1608	1609	%
O	1610	1611	(
O	1611	1617	hazard
O	1618	1623	ratio
O	1624	1625	=
O	1626	1627	0
O	1627	1628	.
O	1628	1630	21
O	1630	1631	;
O	1632	1634	95
O	1634	1635	%
O	1636	1646	confidence
O	1647	1655	interval
O	1656	1657	[
O	1657	1659	CI
O	1659	1660	]
O	1661	1662	=
O	1663	1664	0
O	1664	1665	.
O	1665	1667	08
O	1668	1670	to
O	1671	1672	0
O	1672	1673	.
O	1673	1675	55
O	1675	1676	)
O	1677	1680	and
B-outcome	1681	1683	ER
I-outcome	1683	1684	+
I-outcome	1685	1693	invasive
I-outcome	1694	1700	breast
I-outcome	1701	1707	cancer
O	1708	1710	by
B-iv-bin-percent	1711	1713	83
I-iv-bin-percent	1713	1714	%
O	1715	1716	(
O	1716	1722	hazard
O	1723	1728	ratio
O	1729	1730	=
O	1731	1732	0
O	1732	1733	.
O	1733	1735	17
O	1735	1736	;
O	1737	1739	95
O	1739	1740	%
O	1741	1743	CI
O	1744	1745	=
O	1746	1747	0
O	1747	1748	.
O	1748	1750	05
O	1751	1753	to
O	1754	1755	0
O	1755	1756	.
O	1756	1758	57
O	1758	1759	)
O	1759	1760	.

O	1761	1764	The
O	1765	1772	effects
O	1773	1775	of
O	1776	1777	0
O	1777	1778	.
O	1778	1779	5
O	1780	1782	mg
O	1783	1785	of
O	1786	1798	lasofoxifene
O	1799	1801	on
B-outcome	1802	1807	total
I-outcome	1808	1814	breast
I-outcome	1815	1821	cancer
O	1822	1826	were
O	1827	1834	similar
O	1835	1845	regardless
O	1846	1848	of
O	1849	1853	Gail
O	1854	1859	score
O	1859	1860	,
O	1861	1868	whereas
O	1869	1872	the
O	1873	1880	effects
O	1881	1885	were
O	1886	1894	markedly
O	1895	1903	stronger
O	1904	1907	for
O	1908	1913	women
O	1914	1918	with
O	1919	1927	baseline
O	1928	1937	estradiol
O	1938	1944	levels
O	1945	1952	greater
O	1953	1957	than
O	1958	1961	the
O	1962	1968	median
O	1969	1970	(
O	1970	1974	odds
O	1975	1980	ratio
O	1981	1982	=
O	1983	1984	0
O	1984	1985	.
O	1985	1987	11
O	1987	1988	;
O	1989	1991	95
O	1991	1992	%
O	1993	1995	CI
O	1996	1997	=
O	1998	1999	0
O	1999	2000	.
O	2000	2002	02
O	2003	2005	to
O	2006	2007	0
O	2007	2008	.
O	2008	2010	51
O	2010	2011	)
O	2012	2014	vs
O	2015	2020	those
O	2021	2025	with
O	2026	2032	levels
O	2033	2037	less
O	2038	2042	than
O	2043	2046	the
O	2047	2053	median
O	2054	2055	(
O	2055	2059	odds
O	2060	2065	ratio
O	2066	2067	=
O	2068	2069	0
O	2069	2070	.
O	2070	2072	78
O	2072	2073	;
O	2074	2076	95
O	2076	2077	%
O	2078	2080	CI
O	2081	2082	=
O	2083	2084	0
O	2084	2085	.
O	2085	2087	16
O	2088	2090	to
O	2091	2092	3
O	2092	2093	.
O	2093	2095	79
O	2095	2096	;
O	2097	2098	P
O	2098	2099	(
O	2099	2110	interaction
O	2110	2111	)
O	2112	2113	=
O	2114	2115	.
O	2115	2117	04
O	2117	2118	)
O	2118	2119	.

O	2120	2121	A
O	2122	2123	0
O	2123	2124	.
O	2124	2125	5
O	2125	2126	-
O	2126	2128	mg
O	2129	2133	dose
O	2134	2136	of
O	2137	2149	lasofoxifene
O	2150	2157	appears
O	2158	2160	to
O	2161	2167	reduce
O	2168	2171	the
O	2172	2177	risks
O	2178	2180	of
O	2181	2185	both
O	2186	2191	total
O	2192	2195	and
O	2196	2198	ER
O	2198	2199	+
O	2200	2208	invasive
O	2209	2215	breast
O	2216	2222	cancer
O	2223	2225	in
O	2226	2240	postmenopausal
O	2241	2246	women
O	2247	2251	with
O	2252	2264	osteoporosis
O	2264	2265	.
